The company has collaboration agreements with the Foundation for Biomedical Research at the Puerta de Hierro University Hospital (Madrid, Spain) focused on conducting immunogenicity, pharmacokinetics and biodistribution studies in mice; the Centre for Applied Medical Research (CIMA, Pamplona, Spain) to address the in vivo efficacy of Trimerbody-based molecules in experimental models of cancer; and the Research Biomedicine Institute Alberto Sols (IIBm, Madrid, Spain) to assess the intracellular signaling events induced by specific candidate molecules. In addition, the company is collaborating with the Spanish National Cancer Research Center (CNIO, Madrid, Spain) to address the structures of the Trimerbody-based molecules.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...